Oncology ASCO 2026 reshapes oncology trial design The American Society of Clinical Oncology 2026 annual meeting showcased how, across tumour types, new cancer therapies are achieving deeper responses, extending survival and increasingly mo
Oncology ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o... For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?
Oncology Liquid biopsy and the future of tumour-agnostic treatments Liquid biopsy-based tools are positioned as a critical enabler of tumour-agnostic therapeutic development.
Oncology Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.
Oncology ASCO 2026: Powerful evidence for the microbiome in oncology,... Can the state of someone’s gut microbiome – the balance of good and bad bacteria in their digestive tract – affect their response to cancer immunother
Oncology Bridging the cancer drug development gap: AI-driven precisio... Functional precision oncology gives physicians the data they need to make better decisions about each patient’s care.
News CARSgen bags world-first approval for solid tumour CAR-T CARSgen Therapeutics has claimed approval in China for gastric cancer therapy satri-cel, the first CAR-T to be cleared for a solid tumour.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.